KR890012670A - Antiviral formulation - Google Patents
Antiviral formulation Download PDFInfo
- Publication number
- KR890012670A KR890012670A KR1019890001620A KR890001620A KR890012670A KR 890012670 A KR890012670 A KR 890012670A KR 1019890001620 A KR1019890001620 A KR 1019890001620A KR 890001620 A KR890001620 A KR 890001620A KR 890012670 A KR890012670 A KR 890012670A
- Authority
- KR
- South Korea
- Prior art keywords
- interferon
- component
- hybrid
- alanyl
- acetyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Described is a synergistic pharmaceutical combination preparation comprising as component A a hybrid alpha -interferon the structure of which is derived from human interferon- alpha -D and - alpha -B gene fragments and as component B a muramylpeptide. Said preparation can be used for treating viral diseases or reducing the formation of metastases of certain tumors.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.
Claims (11)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8803365 | 1988-02-13 | ||
CH8803365 | 1988-02-13 | ||
GB888803365A GB8803365D0 (en) | 1988-02-13 | 1988-02-13 | Antiviral combination |
Publications (2)
Publication Number | Publication Date |
---|---|
KR890012670A true KR890012670A (en) | 1989-09-18 |
KR0131077B1 KR0131077B1 (en) | 1998-04-17 |
Family
ID=10631664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890001620A KR0131077B1 (en) | 1988-02-13 | 1989-02-13 | Antiviral combination |
Country Status (15)
Country | Link |
---|---|
US (1) | US5137720A (en) |
EP (1) | EP0329609B1 (en) |
JP (1) | JP2781191B2 (en) |
KR (1) | KR0131077B1 (en) |
AT (1) | ATE99953T1 (en) |
AU (1) | AU623876B2 (en) |
CA (1) | CA1336578C (en) |
DE (1) | DE68912155T2 (en) |
DK (1) | DK62089A (en) |
GB (1) | GB8803365D0 (en) |
IE (1) | IE63493B1 (en) |
IL (1) | IL89248A (en) |
NZ (1) | NZ227944A (en) |
PH (1) | PH26919A (en) |
ZA (1) | ZA891053B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW218846B (en) * | 1992-04-07 | 1994-01-11 | Ciba Geigy | |
FR2702659B1 (en) * | 1993-03-19 | 1995-08-25 | Vacsyn Sa | Compositions for application in human therapy, characterized by the association of a muramyl-peptide with a cytokine. |
DK0689449T3 (en) * | 1993-03-19 | 2003-03-03 | Vacsyn Sa | Preparations for use in human therapy, characterized by combining a muramyl peptide with a cytokine |
US5461512A (en) * | 1993-11-30 | 1995-10-24 | Eastman Kodak Company | Zoom camera lens having three moving groups |
DK0708085T3 (en) * | 1994-10-19 | 2002-11-11 | Novartis Ag | Antiviral ethers of aspartate protease substrate isosters |
US5786214A (en) * | 1994-12-15 | 1998-07-28 | Spinal Cord Society | pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system |
CZ304942B6 (en) | 2000-03-31 | 2015-02-04 | Purdue Research Foundation | Medicament for increasing specific elimination of tumor cell population and pharmaceutical composition containing phosphate-FITC conjugate or phosphate-dinitrophenyl |
CA2461877A1 (en) * | 2001-09-28 | 2003-04-10 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
US20030180348A1 (en) * | 2002-03-22 | 2003-09-25 | Levinson R. Saul | Transcellular drug delivery system |
WO2007092299A2 (en) * | 2006-02-03 | 2007-08-16 | Purdue Research Foundation | Targeted conjugates and radiation |
US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
US20080317836A1 (en) * | 2007-06-19 | 2008-12-25 | Discovery Partners Llc | Topical compositions for anti-aging skin treatment |
RU2488405C1 (en) * | 2012-07-17 | 2013-07-27 | Илья Александрович Марков | Drug herpferon-2 possessing antiviral, anti-inflammatory, immunomodulatory and analgesic action for local and external application |
KR101658048B1 (en) | 2014-06-25 | 2016-09-20 | 한국생명공학연구원 | Anti-viral composition comprising compounds related to phosphatidylcholine synthetic pathway |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS616000A (en) * | 1984-06-21 | 1986-01-11 | 木下 菊巳 | Rotary color matching disk |
ATE78262T1 (en) * | 1985-06-11 | 1992-08-15 | Ciba Geigy Ag | HYBRID INTERFERONS. |
US4774085A (en) * | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
AU603820B2 (en) * | 1986-08-13 | 1990-11-29 | Takeda Chemical Industries Ltd. | Antitumor agent |
-
1988
- 1988-02-13 GB GB888803365A patent/GB8803365D0/en active Pending
-
1989
- 1989-01-31 AU AU28943/89A patent/AU623876B2/en not_active Expired
- 1989-02-06 DE DE68912155T patent/DE68912155T2/en not_active Expired - Lifetime
- 1989-02-06 AT AT89810100T patent/ATE99953T1/en not_active IP Right Cessation
- 1989-02-06 EP EP89810100A patent/EP0329609B1/en not_active Expired - Lifetime
- 1989-02-10 IE IE43589A patent/IE63493B1/en not_active IP Right Cessation
- 1989-02-10 ZA ZA891053A patent/ZA891053B/en unknown
- 1989-02-10 NZ NZ227944A patent/NZ227944A/en unknown
- 1989-02-10 CA CA000590716A patent/CA1336578C/en not_active Expired - Fee Related
- 1989-02-10 JP JP1030039A patent/JP2781191B2/en not_active Expired - Lifetime
- 1989-02-10 DK DK062089A patent/DK62089A/en not_active Application Discontinuation
- 1989-02-10 IL IL8924889A patent/IL89248A/en unknown
- 1989-02-10 PH PH38183A patent/PH26919A/en unknown
- 1989-02-13 KR KR1019890001620A patent/KR0131077B1/en not_active IP Right Cessation
-
1991
- 1991-08-20 US US07/750,711 patent/US5137720A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0329609A2 (en) | 1989-08-23 |
IE890435L (en) | 1989-08-13 |
DE68912155T2 (en) | 1994-06-16 |
KR0131077B1 (en) | 1998-04-17 |
DK62089A (en) | 1989-08-14 |
EP0329609B1 (en) | 1994-01-12 |
CA1336578C (en) | 1995-08-08 |
NZ227944A (en) | 1991-08-27 |
PH26919A (en) | 1992-12-03 |
ZA891053B (en) | 1989-10-25 |
EP0329609A3 (en) | 1990-05-16 |
GB8803365D0 (en) | 1988-03-16 |
IL89248A (en) | 1994-01-25 |
JPH021410A (en) | 1990-01-05 |
AU2894389A (en) | 1989-08-17 |
ATE99953T1 (en) | 1994-01-15 |
IE63493B1 (en) | 1995-05-03 |
JP2781191B2 (en) | 1998-07-30 |
DK62089D0 (en) | 1989-02-10 |
US5137720A (en) | 1992-08-11 |
AU623876B2 (en) | 1992-05-28 |
IL89248A0 (en) | 1989-09-10 |
DE68912155D1 (en) | 1994-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890012670A (en) | Antiviral formulation | |
ES2210864T5 (en) | USE OF A CONSENSUS INTERFERON TO REDUCE THE SIDE EFFECTS OF TREATMENT WITH INTERFER IN VIRIC HEPATITIS. | |
EP0858343B1 (en) | Continuous low-dose cytokine infusion therapy | |
ES2418833T3 (en) | Stabilized interferon liquid formulations | |
CA2120944A1 (en) | Stabilization of human interferon | |
CA1322713C (en) | Compositions and methods for modulating the effect of tnf and il-1 | |
Brunda et al. | Inhibition of experimentally‐induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases | |
BR1100637A (en) | "recombinant turkey herpes virus (hvt), recombinant hvt, nucleic acid sequence, molecupara the preparation of a recombinant hvt, culture a vaccine, process for the preparation of a vaccine, pharmaceutical or diagnostic composition and antiserum" | |
NO169638C (en) | FORMULATION MIXTURE WITH STABILIZING EFFECT ON ALFA INTERFERON | |
STRINGFELLOW et al. | Interferon induction by 5-halo-6-phenyl pyrimidinones | |
OLESZAK et al. | Platelet-derived growth factor (PDGF) inhibits antiviral and anticellular action of interferon in synchronized mouse or human cells | |
JP3496937B2 (en) | Medical composition containing consensus human interferon for treating cell proliferative disorders | |
EP0225759B1 (en) | Interferon compositions | |
Turano et al. | Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine. | |
KR950701638A (en) | Antiviral phosphonic acid derivatives of purine analogues | |
Sehgal et al. | Interferon and its inducers | |
HUGHES et al. | Do the interferons act singly or in combination? | |
EP0956040B1 (en) | Stimulation of host defense mechanisms against viral challenges | |
Werenne et al. | Antiviral effect of bacterially produced human interferon (Hu-IFNα2) against experimental vaccinia infection in calves | |
CA1336491C (en) | Antiviral pharmaceutical composition | |
Eppstein et al. | Liposomal interferon-β: sustained release treatment of simian varicella virus infection in monkeys | |
Cantell et al. | Circulating interferon in rabbits after simultaneous intramuscular administration of human alpha and gamma interferons | |
Cerruti et al. | Synergistic interaction between interferon-α and acyclovir in the treatment of herpes simplex virus type 1 infection in mice | |
CA2302834A1 (en) | Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c | |
Creasey et al. | Advances in interferon research-Medical Staff Conference. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
N231 | Notification of change of applicant | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20081126 Year of fee payment: 12 |
|
LAPS | Lapse due to unpaid annual fee |